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ABSTRACT 
 
Background: Many epithelial ovarian cancer (EOC) risk factors relate to hormone 
exposure, and elevated estrogen levels are associated with obesity in post-menopausal 
women. Therefore, we hypothesized that gene-environment interactions related to 
hormone-related risk factors could differ between obese and non-obese women. 
Methods: We considered interactions between 11,441 single nucleotide polymorphisms 
(SNPs) within 80 candidate genes related to hormone biosynthesis & metabolism and 
insulin-like growth factors with six hormone-related factors: oral contraceptive use; parity; 
endometriosis; tubal ligation; hormone replacement therapy; and estrogen use; and 
assessed whether these interactions differed between obese and non-obese women.  
Interactions were assessed using logistic regression models and data from 14 case-control 
studies (6,247 cases; 10,379 controls). Histotype specific analyses were also completed.  
Results: SNPs in the following candidate genes showed notable interaction: IGF1R 
(rs41497346, estrogen plus progesterone hormone therapy, histology = all, p = 4.9x10-6) 
and ESR1 (rs12661437, endometriosis, histology = all, p = 1.5x10-5). The most notable 
obesity - gene - hormone risk factor interaction was within INSR (rs113759408, parity, 
histology = endometrioid, p = 8.8x10-6). 
Conclusions: We have demonstrated the feasibility of assessing multi-factor interactions 
in large genetic epidemiology studies. Follow-up studies are necessary to assess the 
robustness of our findings for ESR1, CYP11A1, IGF1R, CYP11B1, INSR, and IGFBP2. 
Future work is needed to develop powerful statistical methods able to detect these complex 
interactions.  
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Impact: Assessment of multifactor interaction is feasible, and, here, suggest that the 
relationship between genetic variants within candidate genes and hormone-related risk 
factors may vary EOC susceptibility. 
Keywords: body mass index; obesity; hormone related factors; SNP; gene-environment 
interaction; ovarian cancer;  
 
Category: Epidemiology 
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INTRODUCTION  
 
Little research has been conducted to determine multifactor gene-environment 
interaction at the candidate gene or genome-wide level despite the emerging evidence to 
show that these types of complex relationships do exist (1-3). In addition to the lack of 
studies assessing complex interactions in cancer risk, only a limited number of studies have 
assessed gene-environment (GE) interactions by histological subtype, as genetic and 
environmental risk factors have been found to differ by the histology. Recently, consortia 
have been established to give the large sample size needed to detect SNPs with small 
effects, providing the ability to study GE interactions. In April 2005, the Ovarian Cancer 
Association Consortium (OCAC) was formed; the largest international consortium 
conducting genetic epidemiology studies for epithelial ovarian cancer (EOC) (4). This 
international effort comprises more than 40 different genetic epidemiological studies, with 
the focus on assessing single SNP associations with EOC.  
To date, OCAC has identified 18 confirmed novel susceptibility loci that are 
associated with EOC risk (5-12). In addition to finding new risk loci, GWAS also confirm 
the biological distinction of the various EOC histologies. For example, risk alleles in 8q24 
and 19p13 associate almost exclusively with serous EOC (8, 13), yet those in 2q31 and 
17q12 are also associated with other subtypes (8, 14). However, it is hypothesized that the 
known risk loci are likely to represent only a fraction of the common risk alleles for EOC 
and that numerous undetected common variant loci still remain to be discovered (15).  
 In addition to genetic susceptibility loci, there are several confirmed EOC 
environmental risk factors. Similar to other hormone-related cancers in women, many of 
these risk factors related to hormone exposure, including: obesity (risk) (16-19); history of 
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endometriosis (risk) (20); estrogen use menopausal hormonal therapy (MHT) (risk) (21); 
estrogen plus progesterone MHT (risk) (21); oral contraceptive use (protective effect that 
increases with time of use) (22); parity (protective effect increases with number of live 
births) (23, 24); tubal ligation (protective) (25); and breast feeding (protective) (26, 27). 
Similar to genetic risk factors, environmental risk factors also differ by histology (28); for 
example, endometriosis is associated with risk of only clear cell, low-grade serous, and 
endometrioid EOC (20, 29). The vast majority of epidemiological studies of EOC risk have 
focused on marginal effects of genetic and environmental factors.  A recent study by OCAC 
investigators assessed GE interactions across six known genetic risk loci (30). While this 
study looked at GE by histotype, this study did not investigate a three-way interaction 
involving obesity. 
 Obesity is associated with an increase in insulin levels, resulting in an increase in 
insulin-like growth factor 1 (IGF1) activity (31, 32). Increased levels of adiposity also lead 
to increased aromatase activity, and thus to an increase in estrogen levels (31, 33-35). After 
menopause, adipose tissue is the major source of estrogen in women. In breast cancer, 
evidence suggests that increased estrogen levels might underlie the association between 
BMI, breast cancer risk and MHT (31). It has been found that in post-menopausal women, 
the association between breast cancer and BMI is stronger in women who have never 
received MHT, compared with women who have used MHT (36). Similarly, a recent meta-
analysis (2012) found that use of MHT attenuated the effect of BMI on EOC risk (17). A 
recent OCAC study found that high BMI was associated with increased risk of EOC in 15 
case-control studies (16). In addition to finding an association between BMI and EOC risk, 
they found that this association was more pronounced in borderline serous, invasive 
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endometrioid, and invasive mucinous histotypes. However, they found that MHT did not 
attenuate the effect of BMI on EOC risk when the analyses were restricted to post-
menopausal women. Additionally, they also found no association of BMI with risk of 
ovarian cancer in the most common serous histotype (16). Based on these data, we 
hypothesize that GE effects could differ between obese and non-obese women.  
Based on the complex relationship between hormone exposure, obesity, growth 
factors / insulin levels, and genetic factors we hypothesize that GE effects could be 
histology dependent and differ between obese and non-obese women. This hypothesis is 
illustrated in Supplemental Figure 1. In this candidate gene study, we sought to detect 
both two-way and multifactor obesity-gene-environment interactions for EOC risk. 
Overall, we assessed 11,441 SNPs located within 80 candidate genes related to hormone 
biosynthesis and metabolism in addition to those in insulin-like growth factors. The case-
control analyses were run separately for case groups that involve: (1) all EOC invasive 
cases; (2) high-grade serous (HGS) invasive cases; and (3) endometrioid (ENDO) invasive 
cases. Candidate gene analyses specific to the less common histotypes were excluded due 
to the difficulty of assessing three-way interactions.   
 
MATERIALS AND METHODS  
Study Participants 
 Supplemental Tables 1 and 2 summarize the characteristics of the 14 OCAC 
studies used to assess GE interactions (37-49). The 14 studies included in this analysis were 
part of the Collaborative Oncological Gene Environment Consortium (COGS) study in 
which approximately 200,000 SNPs were genotyped in breast, ovarian and prostate 
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cancers. Each OCAC study included in the analyses had to contribute at least 50 ovarian 
cancer cases and 50 controls, with controls further required to be sampled from the same 
population as the cases. Thus, 6,247 invasive cases and 10,379 controls of European 
descent were included in this analysis. GE interactions have been explored in these studies 
previously (28) and are described in further detail therein. Each study provided information 
on age at diagnosis or enrollment, BMI and other reproductive and lifestyle factors as well 
as information regarding tumor histology (serous, endometrioid, clear cell, mixed, other), 
tumor behavior (invasive or borderline), and tumor grade (well differentiated, moderately 
differentiated, poorly differentiated, undifferentiated). All patients provided informed 
consent, including for passive and active follow-up, using protocols approved by the 
appropriate Institutional Review Board. Table 1 describes the clinical features of EOC 
cases (6247 all EOC, 3019 HGS, 961 ENDO) and controls (N = 10379). 
Environmental and Genetic Risk Factors 
Young Adult BMI 
              To quantify obesity we used BMI calculated in early adulthood (18-29 years of 
age) as opposed to BMI at diagnosis as early adulthood BMI would better approximate 
subjects obesity levels integrated over a lifetime (18, 50), and thus exposure to estrogen 
derived from adipose tissue. Measurement of weight in early adulthood was conducted in 
9 of the 14 studies used for the GE analyses (16); and therefore the three-way BMI-GE 
interaction analyses were limited to these 9 studies. Five studies reported weight at age 18 
(DOV, HAW, HOP, POL, UCI), two studies reported weight ‘in your 20s’ (MAL, USC), 
and two studies reported weight at age 20 (AUS, GER). The calculated BMIs were 
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classified according World Health Organization (WHO) standards: (<18.5 ‘underweight’; 
18.5–24.9 ‘normal weight’; 25–29.9 ‘overweight’; 30-34.9 ‘class I obesity’; 35-39.9 ‘class 
II obesity’; and ≥40 ‘class III obesity’) (51). From these WHO standards the subjects BMI 
were further categorized into two groups for GE analyses: (1) underweight or normal 
weight individuals with BMI less than 25 and (2) overweight or obese individuals BMI 
greater than 25.  
Hormone-Related Environmental Factors 
 The GE analyses included seven hormone-related environmental factors: oral 
contraceptive use, parity, breast feeding, tubal ligation status, endometriosis, estrogen 
MHT, and estrogen plus progesterone MHT. To facilitate testing for multifactor 
interactions each environmental factor was dichotomized to ensure reasonable sample sizes 
in the various groups. Oral contraceptive use (years) was divided into (< 1 year; >= 1 year), 
parity (0 full births;  >= 1 full birth), breast feeding was separated into (ever/never), 
estrogen MHT and estrogen plus progesterone MHT were categorized as (never/ever), 
while endometriosis and tubal ligation were included in terms of yes/no status.  
Genetic Markers 
 We searched the literature to determine a set of candidate genes related to steroid 
biosynthesis, estrogen signaling and insulin-like growth factors (IGFs), as we hypothesize 
that genetic variants within these candidate genes modify EOC risk and that these effects 
are modified by hormone-related risk factors and obesity (52-54), and identified a list of 
80 candidate genes (Supplemental Table 3). Using the National Center for Biotechnology 
Information (NCBI) website, SNPs were selected within 20 Kb of the first or last exon, as 
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this was expected to sufficiently cover the promoter regions of most genes, as well as SNPs 
in LD with variation in the gene region (55). Due to power limitations for testing 
multifactor gene-environment interactions, SNPs were excluded from the analysis if the 
minor allele frequency (MAF) was less than 10%. This approach extracted 11,441 
candidate gene SNPs. The candidate gene SNPs were imputed using the 1000 Genomes 
project (56), from an original set of > 200,000 genotyped SNPs from the COGS custom 
Illumina SNP array (57, 58). Details on the number of imputed SNPs for each candidate 
gene are included in (Supplemental Table 3).  
Statistical Analysis 
 The study population was restricted to individuals of European descent based on 
LAMP analyses (59) with complete covariate information; and only invasive EOC cases 
were considered. For analyses involving the MHTs, either estrogen use or estrogen plus 
progesterone (EPP) use, the cases and controls were further restricted to post-menopausal 
women. For both the GE and BMI-GE (or GEE) analyses, the presence or absence of the 
environmental factors were coded as either 0 or 1. Separate analyses were conducted for 
case groups that included: (1) all invasive EOC cases, (2) HGS cases, and (3) ENDO cases. 
Analyses were adjusted for age of diagnosis (enrollment), study site and the first 5 principal 
component scores from a principal component analysis to adjust for population 
substructure. With the goal to determine gene-environmental effects and not general 
genetic association, assessment of significance was restricted to the higher level interaction 
effects (as opposed to “omnibus” tests for both genetic main and interaction effects(60)).   
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The following logistic regression model was used to assess gene-environment 
interaction for each SNP. For i = 1,…,n let   
logit P(D𝑖 = 1|G𝑖𝑗 , E𝑖𝑘, Z𝑖) =  β0 + βGG𝑖𝑗 + βEE𝑖𝑘 +  βGEG𝑖𝑗E𝑖𝑘 + Z𝑖βZ,  
where Di represents that disease status (case =1, control = 0) for subject i , Gij represents 
the number of minor alleles observed for subject i for SNP j, Eik represents the absence or 
presence of environmental factor k for subject i, and Zi represents a vector of covariates for 
subject i to account for potential confounding, and each 𝛽𝐺𝐸 represents a corresponding 
interaction regression coefficient. For each SNP j and environmental factor k we tested the 
null hypothesis of no GE interaction versus an alternative hypothesis that a GE interaction 
is present (i.e., null hypothsis: βGE = 0   vs.  alternative hypothesis:  βGE ≠ 0 ). The 
hypothesis was tested with the likelihood ratio test statistic  𝐷 =
−2 ln (
likelihood for reduced (null))model
likelihood for full (alternative)model
) ~𝜒1
2 .  
 Similarly, to test whether GE interactions could be modified by BMI we considered 
the following logistic regression model. For i = 1,…n let  
logit 𝑃(𝐷𝑖 = 1|𝐺𝑗 , 𝐸1𝑖 , 𝐸2𝑖𝑘, 𝑍𝑖) =  𝛽0 + 𝛽𝐺𝐺𝑗 + 𝛽𝐸1𝐸1𝑖 + 𝛽𝐸2𝐸2𝑖 + 𝛽𝐺𝐸1𝐺𝑗𝐸1𝑖 +
𝛽𝐺𝐸2𝐺𝑗𝐸2𝑖 + 𝛽𝐸1𝐸2𝐸1𝑖𝐸2𝑖 + 𝛽𝐺𝐸𝐸𝐺𝑗𝐸1𝑖𝐸2𝑖 + 𝑍𝑖𝛽𝑍, 
where E1i represents the BMI status (low/high) at young adulthood of subject i, E2i  
represents the presence of absence of the second environmental factor for subject i, and Zi 
represents a vector of covariates for subject i that account for potential confounding, and 
each 𝛽 represents a corresponding regression coefficient. To test whether GE interactions 
differ between non-obese and obese individuals we test the null hypothesis of no GEE 
interaction versus an alternative hypothesis of GEE interaction is present (i.e., null 
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hypothesis  𝛽𝐺𝐸𝐸 = 0 versus alternative hypothesis ∶   𝛽𝐺𝐸𝐸 ≠ 0 ). This hypothesis was 
tested using a likelihood ratio test statistic 𝐷 = −2 ln (
likelihood for reduced (null)model
likelihood for full (alternative)model
) 
~𝜒1
2 .  
 
RESULTS 
Gene-Environment Interaction  
In total, the GE analyses were run across 11,441 candidate gene SNPs, and included 91,528 
GE combinations (11,441 SNPs x (7 Environmental Factors + BMI)), and these analyses 
were run across 3 separate case groups (All, HGS, ENDO). However, the imputed SNPs 
were in high linkage disequilibrium, and the analyses across case groups were also highly 
correlated. The SimpleM method was used to estimate the effective number of independent 
SNPs tested within each gene (61) (Supplemental Table 3); and in total the analyses were 
estimated to involve independent 2336 SNPs. Using the estimated effective number of 
independent tests, the Bonferroni corrections for the number of total candidate gene SNPs 
was 0.05/2,336 = 2.1 x 10-5, while adjusting for the total number of independent GE 
combinations gives 0.05/(2,336 x 8) = 2.7 x 10-6 respectively. Several SNP-environment 
interactions were significant using the former threshold, however using the latter strict 
threshold, no significant GE was detected. SNPs with GE interaction p < 10-4 are presented 
in Table 2.  
 Figure 1 provides an image map that highlights interaction tests of environmental 
factors and candidate genes with at least one SNP p-value less than pre-defined significance 
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thresholds: p = 10-3, p = 10-4, and p = 10-5. Within this plot, the candidate genes are grouped 
alphabetically according to their involvement in the production of hormones hypothesized 
to influence EOC risk (62) (Androgen, Estrogen, Progesterone, Gonadotropins, Insulin-
related). A full list of SNPs with minimum p-values (p < 10-3) in candidate genes for the 
GE interaction analyses are presented in Supplemental Table 4.  
The most statistically significant GE-interaction was IGF1R (rs41497346, estrogen 
plus progesterone (EPP) MHT, histology = all, OR = .56, p = 4.9 x 10-6) (Figures 2a, 2b). 
The marginal odds ratio estimate of rs41497346 was .96 (p = .12). However, within non - 
EPP MHT users the presence of a minor allele increased risk for EOC (OR = 1.29); while 
within EPP MHT users rs41497346 provided a protective effect (OR = 0.72). The 
rs41497346 – EPP MHT interaction estimates were qualitatively similar across each 
histology included in our candidate gene analyses: HGS (OR = .55, p = 1.7x10-4), and 
ENDO (OR = .77, p = .38). The next most significant GE interaction result included ESR1 
(rs12661437, endometriosis, histology = all, OR = 1.71, p = 1.5 x 10-5) (Figures 2c and 
2d), where the minor allele decreased EOC risk in patients with no endometriosis and 
increased risk in patients with endometriosis. The marginal odds ratio estimate of 
rs12661437 was .95 (p = .17). However, within women with no endometriosis history, the 
presence of a rs12661437 minor allele decreased risk for EOC (OR = .92); while within 
women with a history of endometriosis, the rs12661437 minor allele provided increased 
risk (OR = 1.59). Subtype specific analyses for rs12661437 also found qualitatively similar 
effect sizes across all histologies (Supplemental Table 4). Rs12661437 lies in an intron 
near the 5’ end of ESR1. 
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When restricting the cases to HGS, the most notable interaction was for CYP11A1 
(rs9944175, endometriosis, histology = HGS, OR = .42, p = 4.1 x 10-5) (Figures 2e and 
2f). The marginal odds ratio estimate for HGS EOC risk of rs9944175 was 1.06 (p = .26). 
However, for women with no history of endometriosis, the estimated effect of one 
rs9944175 minor allele increased HGS EOC risk (OR = 1.1) but decreased HGS EOC risk 
in women with a history of endometriosis (OR = .47). This SNP showed no statistically 
significant interaction for the ENDO histology (OR = .69, p = .18). rs9944175 lies within 
20Kb of the 3’ end of CYP11A1. 
Multifactor or BMI-Gene-Environment Interactions 
For each gene, SNPs with notable BMI-GE interaction results (p < 10-3) and their estimated 
interaction effects are presented (Supplemental Table 5). Figure 3 provides an image map 
that highlights 3-way interaction tests of obesity, lifestyle and reproductive factors, and 
candidate genes with at least on SNP p-value less than: p = 10-3, p = 10-4, and p = 10-5. This 
image map groups the candidate genes alphabetically and according to their involvement 
in the production of hormones hypothesized to influence EOC risk (62) (Androgen, 
Estrogen, Progesterone, Gonadotropins, Insulin-related). No statistically significant SNPs 
were detected after Bonferroni correction for the effective number of candidate gene SNPs 
(p < 2.1 x 10-5). A stricter threshold that adjusts for effective number of candidate gene 
SNPs by 7 environmental factors in the BMI-GE analyses was p < 3.1 x 10-6.  
 The most statistically significant SNP for the BMI-GE analyses lies in INSR 
(rs8102954, parity, histology = ENDO, BMI-GE OR = .074, p = 8.83 x 10-6) (Figures 4a 
and 4b). Within the low BMI women group the estimated SNP – Parity interaction of one 
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rs8102954 minor allele for the ENDO cases was negligible (OR GElow BMI = 1.4, p = .15); 
while within high BMI women the estimated GE effect is (OR GEhigh BMI = .10, p = .0021). 
The BMI – GE interaction effect was not significant for analyses with case groups that 
included all histology and high-grade serous cases. rs8102954 lies in a exonic region near 
the 3’ end on INSR.   
 For case-controls analyses including all histologies, the most notable BMI-GE 
interaction was IGFBP2 (rs869564, parity, histology = All, BMI – GE OR = .096, p = 1.43 
x 10-5) (Figures 4c and 4d). For low BMI women the estimated SNP – parity interaction 
effect of one rs869564 minor allele was negligible (OR GElow BMI, p = .48); however within 
high-BMI women the estimated GE interaction effect was (OR GEhigh BMI = .11, p = 4.14 x 
10-5). The three-way BMI-GE interaction effect was significant for the HGS cases (BMI – 
GE OR = .077, p = 1.23 x 10-3), but not the analyses involving the ENDO cases (BMI – 
GE OR = p = .18). rs869564 resides in an exonic region on the 3’ end of IGFBP2.  
 For HGS cases, the most statistically significant SNP for the BMI-GE analyses lies 
in CYP11B1 (rs113759408, oral contraceptive use, histology = HGS, BMI-GE OR = .072, 
p = 2.2 x 10-5) (Figures 4e and 4f). Within the low BMI women group the estimated SNP-
OC use interaction effect of one rs113759408 minor allele for HGS cases was negligible 
(OR GElow BMI= -.90, p = .41); while within high BMI women the estimated GE effect is 
large (OR GEhigh BMI = 4.52, p = .0028). The BMI-GE interaction effect was not statistically 
significant for the ENDO histology (BMI-GE OR= 2.11, p=.24). rs113759408 lies in an 
intronic region in the middle of CYP11B1.  
DISCUSSION 
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In this paper, we investigated both gene-environment and multifactor obesity-gene 
environment interactions in epithelial ovarian cancer (EOC) risk. We used 14 case-control 
studies within the Collaborative Oncological Gene Environment Consortium (COGS) and 
Ovarian Cancer Association Consortium (OCAC) that provided more than 6,000 cases and 
10,000 controls. Our main hypothesis was that some EOC risk due to SNPs could be 
explained by interactions with environmental factors. Similar to breast and endometrial 
cancers, many EOC risk factors relate to hormone exposure, and increased levels of 
estrogen has been associated with obesity in post-menopausal women. Therefore, we 
hypothesized that gene-environment interactions dealing with hormone-related risk factors 
could differ between obese and non-obese women. None of the tests of gene-environment 
interaction and multi-factor obesity-gene-environment interaction were significant at 
genome-wide level (p = 5x10-8).  
The most statistically significant gene-environment interaction result was IGF1R 
(rs41497346, estrogen plus progesterone MHT, Histology = All, OR = 0.56, p = 4.9 x 10-
6). Rs41497346 lies in an intronic region near the 3’ end of IGF1R, and is in the same 
linkage disequilibrium block as several SNPs hypothesized to have marginal risk in breast 
cancer (63). High expression levels of IGF1R were reported by Tang et al (64) in tumor 
tissue samples from 25 of 36 patients with epithelial ovarian cancer. Estrogen use is 
associated with increased IGF1R expression, while progesterone was associated with 
decreased IGF1R expression in breast cancer cells (65).  Variation within the gene ESR1 
was also found to be involved in an interaction involving endometriosis in analyses of all 
histologies (rs12661437, intronic SNP near 5’ end of gene, p = 1.5 x 10-5), where the minor 
allele decreased EOC risk in patients with no endometriosis and increased risk in patients 
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with endometriosis.  Subtype specific analyses for rs12661437 also found qualitatively 
similar effect sizes across all histologies. Variation near ESR1 (rs2295190) has been 
reported to be associated with EOC risk (66); however the SNPs are in low LD (r2 = 0.001). 
For the BMI-GE interaction analyses, the most statistically significant results were 
INSR (rs8102954, parity, histology = ENDO, BMI-GE OR = 0.074, p = 8.83 x 10-6) 
(Figures 4a and 4b) and IGFBP2 (rs869564, parity, histology = All, BMI – GE OR = 
0.096, p = 1.43 x 10-5) (Figures 4c and 4d). No genetic polymorphisms within INSR and 
IGFBP2 have been associated previously with ovarian cancer risk.  Nevertheless, 
considerable research exists on the role of insulin receptors and cancer as studies have 
shown that insulin receptors may be involved in the regulation of ovarian cancer cell 
growth(67) and that increased levels of insulin have been associated with breast and 
endometrium cancers for which these tumorigenic properties can be modified by insulin 
receptors (31). Similarly, the role of insulin-like growth factors (IGFs) have been extensive 
studied for their role in carcinogenesis(68). Specifically, IGFBP2 has been linked ovarian 
cancer by promoting cancer cell invasion(69), while common variants in IGF1, IGFBP1 
and IGFBP3 have been associated with ovarian (70) and endometrial cancers (71).  
IGFBP2 has also been linked to other hormone-related cancers (72-74).  
For the high-grade serous cases, the most statistically significant SNP for the BMI-
GE analyses lies in CYP11B1 (rs113759408, oral contraceptive use, Histology = HGS, 
BMI-GE estimate = 1.49, p = 2.2 x 10-5) (Figures 4e and 4f). Polymorphism rs113759408 
lies in an intronic region in the middle of CYP11B1 (between exons 3 and 4), the gene that 
encodes for steroid 11beta-hydroxylase. Mutations in this gene cause congenital adrenal 
hyperplasia (OMIM #202010).  No research has been published showing a link between 
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EOC risk and variants within this gene. However, genetic variation in CYP11B1 has been 
reported to be associated with breast cancer risk from a prediction model involving SNP 
rs4541 in exon 7 of CYP11B1 (75) and the association with serum hormone levels in breast 
cancer patients (76) .  
 We chose to restrict our analyses to SNPs located within 80 candidate gene and 8 
established ovarian cancer reproductive or lifestyle factors. An earlier study investigated 
2-way interactions between 6 established SNP risk loci and 5 established environmental 
risk factors (30).  Similar to our study results, their 2-way interaction analyses were not 
strong enough to rule out the role of chance. While these initial findings suggest that gene-
environment interactions play a modest role in EOC risk, genome-wide studies are 
necessary to fully examine the potential interplay between SNPs and environmental 
factors.  
 For the obesity-gene-environment analyses, a strength of this study was the use of 
young adult BMI (low, high) as opposed to BMI at diagnosis, since young adult BMI may 
serve as an indicator of obesity integrated over a life-time and adipose-based estrogen 
exposure (18, 50).  While a biological rationale exists for higher-order interactions, very 
little literature has focused on multi-factor interactions, perhaps due to the challenge of 
necessary power to detect these higher order interactions. Therefore, a limitation of the 
multi-factor gene-environment interaction analyses were modest sample sizes: especially 
for less well documented environmental factors and histology specific analyses 
(Supplemental Tables 6 and 7).  
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 In conclusion, we have demonstrated the feasibility of assessing multi-factor 
interactions in large genetic epidemiology studies. Future work is needed to develop 
powerful statistical methods able to detect these complex interactions, as they may provide 
additional information regarding the genetic etiology of ovarian and other hormone – 
related cancers. Follow-up studies are necessary to assess the robustness of our notable 
findings in ESR1, CYP11A1, IGF1R, CYP11B1, INSR, and IGFBP2.  To further follow-up 
our investigation of multi-factor gene-environment interactions, we will explore other 
potential modifiers of gene-environment risk, such as BRCA mutation status, and assess 
BMI-GE in other hormone-related cancers, such as breast, prostate and endometrial. 
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Table 1: Clinical features in EOC cases & controls included in the GE and BMI-GE analyses. 
Sample sizes vary as not all studies collected data on each lifestyle and reproductive factor. 
Characteristics Controls: N (%) Cases: N (%) P 
Age (years)    <.0001 
  Mean ± SD 57.5 ± 11.6  58.3 (11.0)  
Age (categorical)   <.0001 
    < 50 years  2604 (25.1) 1366 (21.9)  
  50 to 55 years  1424 (13.7) 946 (15.1)  
  55 to 60 years  1691 (16.3) 1071 (17.1)  
  60 to 65 years 1629 (15.7) 1015 (16.2)  
  > 65 years 3031 (29.2) 1849 (29.6)  
Young Adult BMI (kg/m2)   <.0001 
   Underweight/Normal (< 25) 7607 (91.8) 4427 (89.7)  
   Overweight/Obese (> 25) 679 (8.2) 508 (10.3)  
Parity   <.0001 
   (0 full births) 1415 (14.7) 1453 (25.1)  
   (> 0 full births) 8234 (85.3) 4328 (74.9)  
Breast Feed   <.0001 
   No 2312 (30.3) 1641 (39.9)  
   Yes 5320 (69.7) 2467 (60.1)  
Oral contraceptive use    <.0001 
   (<= 2 years) 4895 (47.4) 3487 (57.1)  
   (> 2 years) 5428 (52.6) 2616 (42.9)  
Estrogen use    .44 
   No 3986 (78.9) 2250 (78.1)  
   Yes 1068 (21.1) 631 (21.9)     
EPP MHT Use   <.0001 
   No 3420 (67.7) 2105 (73.3)  
   Yes 1631 (32.3) 765 (26.7)  
Endometriosis    <.0001 
   No 8738 (93.9) 4802 (90.0)  
   Yes 568 (6.1) 533 (10.0)  
Tubal Ligation    <.0001 
   No 6924 (77.8) 4692 (83.5)  
   Yes 1976 (22.2) 926 (16.5)  
Tumor Grade    
   Well-Differentiated  739 (12.1)  
   Moderately Differentiated  1358 (22.2)  
   Poorly Differentiated  2911 (47.6)  
   Undifferentiated  459 (7.5)  
   Other  647 (10.6)  
Histotypes     
   Serous  3589 (57.4)  
   Mucinous  403 (6.5)  
   Endometrioid  961 (15.4)  
   Clear Cell  468 (7.5)  
   Others  827 (13.2)  
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Table 2: Association with p < 10-4 for GE and BMI-GE analyses. Results highlighted in green or red in Figures 1 and 3. More 
detailed summaries of these top hits are shown in Supplemental Tables 4 and 5.  
Analysis Histology Environment Gene SNP MAF N cases N controls Interaction P-value 
GE All EPP MHT   IGF1R rs41497346 0.28 2870 
 
5051 
 
-0.577 4.92 x 10-6 
GE All Endometriosis ESR1 rs12661437 0.34 5335 
 
9306 
 
0.534 1.47 x 10-5 
GE ENDO Estrogen MHT  HSD17B2 rs2955162 0.23 405 
 
5054 
 
-1.12 3.44 x10-5 
GE HGS Endometriosis CYP11A1 rs9944175 0.24 2578 
 
9306 
 
-0.872 4.13 x10-5 
GE ENDO Estrogen MHT AKR1C3 rs61856140 0.10 405 
 
5054 
 
-1.47 5.30 x10-5 
GE ENDO Endometriosis CYP11B2 rs28526467 0.43 815 
 
9306 
 
-1.09 6.83 x10-5 
GE ENDO OC Use PRL rs72836169 0.10 945 
 
10323 
 
-0.827 7.09 x10-5 
BMI-GE ENDO Parity INSR rs8102954 0.37 778 8284 -2.56 8.35x10-6 
 
BMI-GE All Parity IGFBP2 rs869564 0.11 4934 8284 -2.34 1.43x10-5 
 
BMI-GE HGS 
 
OC Use 
 
CYP11B1 
 
rs113759408 
 
0.17 2296 
 
8250 1.49 2.18x10-5 
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Figure Legends: 
 
Figure 1: Image map of top p-values for GE interactions results for 80 candidate gene SNPs and 
7 hormone related environmental factors as well as BMI. 
Figure 2: Locus zoom plots and estimated GE interaction effects of top results for IGF1R-
Combination use (a,b), ESR1-Endometriosis (c,d), and CYP11A1-Endometriosis (e,f). The 
vertical black lines represent 95% confidence intervals for estimated odds ratios. 
Figure 3. Image map of smallest p-values for multi-factor BMI-GE interactions results for 
Candidate Gene SNPs and 7 non-obesity related environmental factors.  
Figure 4. Locus zoom plots and estimated BMI-GE interaction effects of top results for INSR-
Parity-BMI (Histology ENDO) (a,b), IGFBP2-Parity-BMI (Histology All) (c,d), and CYP11B1-
OC Use-BMI (Histology HGS) (e,f). The vertical black lines represent 95% confidence intervals 
for estimated odds ratios. 
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Supplemental Figure 1: Potential Hormonal Mechanism to motivate investigation of 
multi-factor obesity-hormone related risk factors – SNP interactions.  
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Australian Ovarian Cancer Study AUS Australia 2002-2006 Y Y Y Y Y Y Weight at age 20
Diseases of the Ovary and their Evaluation DOV USA 2002-2005 Y Y Y Y Y Y Y Y Weight at age 18
Germany Ovarian Cancer Study GER Germany 1993-1995 Y Y Y Y Y Y Y Y Weight at age 20
Hawaii Ovarian Cancer Study HAW USA 1992-2008 Y Y Y Y Y Y Y Y Weigh at age 18
Hormones and Ovarian Cancer Prediction HOP USA 2003-2009 Y Y Y Y Y Y Y Y Weight at age 18
Danish Malignant Ovarian Tumor Study MAL Denmark 1994-1999 Y Y Y Y Y Y Weight in your 20s
Mayo Clinic Ovarian Cancer Case Control Study MAY USA 2000-2007 Y Y Y Y Y Y Y Not reported
North Carolina Ovarian Cancer Study NCO USA 1999-2008 Y Y Y Y Y Y Not reported
Nijmegen Polygene Study & Nijmegen Biomedical Study NTH Netherlands 2008 Y Y Y Y Y Y Y Y Not reported
Ovarian Case-Control Study in Poland POL Poland 2000-2003 Y Y Y Y Y Y Y Y Weight at age 18
Family Registry for Ovarian Cancer and Genetic Epidemiology STA USA 1997-2001 Y Y Y Not reported
UC Irvine Ovarian Cancer Study UCI USA 1993-2005 Y Y Y Y Y Y Y Weight at age 18
UK Ovarian Cancer Population Study UKO UK Y Y Y Y Y Y Y Not reported
Los Angeles County Case-Control Studies of Ovarian Cancer USC USA 1993-2005 Y Y Y Y Y Y Y Y Weight in your 20s
Supplementary Table 1. Study Sites Information 
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Supplementary Table 2: Sample Sizes by Study Site.
Site Controls All Cases High-Grade Serous Cases Endometrioid Cases
AUS 822 529 288 71
DOV 1461 891 429 143
GER 413 191 82 21
HAW 145 57 34 11
HOP 1435 564 272 83
MAL 822 440 183 54
MAY 800 535 355 93
NCO 808 675 334 109
NTH 322 255 65 65
POL 664 235 96 36
STA 313 246 133 30
UCI 367 280 152 52
UKO 945 672 266 108
USC 1062 677 330 85
Totals 10379 6247 3019 961
Sample sizes correspond to white, non-hispanic women, with non-missing data for age.
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Gene Chromosome Number of COGS SNPs Effect Number of Independent Tests
GSTM1 1 94 40
HSD3B2 1 71 18
HSD3B1 1 159 21
POMC 2 72 19
SRD5A2 2 117 28
CYP1B1 2 119 25
LHCGR 2 268 52
FSHR 2 642 70
INHBB 2 64 26
ACVR2 2 107 22
ACVR1 2 97 28
IGFBP2_5* 2 102 53
INHA 2 61 15
IRS1 2 21 17
UGT1A1_3_4_5_6_7_9_10* 2 355 66
POU1F1 3 73 21
SST 3 82 26
GNRHR 4 99 14
UGT2B17 4 192 34
UGT2B7 4 288 10
SULT1B1 4 122 22
SULT1E1 4 82 19
SRD5A1 5 168 38
PRLR 5 304 53
HSD17B4 5 167 37
PRL 6 98 26
CYP21A2 6 31 20
CGA 6 100 14
ESR1 6 772 152
IGF2R 6 258 78
SHBG 7 147 23
INHBA 7 45 14
IGHBP1_3* 7 128 30
CYP3A4 7 20 10
AKR1D1 7 155 28
GNRH1 8 46 9
STAR 8 17 16
CYP11B1_2* 8 212 26
HSD17B3 9 260 34
AKR1C1_2_3* 10 735 112
AKR1C4 10 207 32
CYP17A1 10 80 22
IGF2 11 159 51
FSHB 11 81 14
GSTP1 11 81 13
PGR 11 346 32
IGFBP6 12 76 26
IGF1 12 82 27
IRS2 13 186 31
SSTR1 14 76 21
ESR2 14 152 37
CYP19A1 15 271 58
CYP11A1 15 98 14
CYP1A1_2* 15 48 24
IGF1R 15 475 128
SSTR5 16 127 43
IGFALS 16 230 18
SULT1A1 16 120 41
HSD17B2 16 111 33
IGFBP4 17 47 22
HSD17B1 17 53 13
SSTR2 17 102 26
INSR 19 599 106
GNRH2 20 113 35
SSTR4 20 86 23
COMT 22 221 44
SSTR3 22 210 27
AR 23 54 9
Totals 11441 2336
* Underscores (_) represent that the results correspond to multiple genes whose SNPs overlap in the analyses. 
Supplementary Table 3. Candidate Gene Summary
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Gene SNP Chromosome Build 37 Position MAF Histology (Most Significant) Environment GE Est (all) OR GE (all) OR no (all) OR yes (all) GE LRT p-value (all) GE Est (HGS) OR GE (HGS) OR no (HGS) OR yes (HGS) GE LRT p-value (HGS) GE Est (Endo) OR GE (Endo) OR no (Endo) OR yes (Endo) GE LRT p-value (Endo)
AKR1C1_2_3 rs61856140 10 5111785 0.15 All Estrogen Use -0.49 0.61 1.11 0.68 3.79E-04 -0.37 0.69 1.02 0.71 2.99E-02 -1.47 0.23 1.36 0.32 5.30E-05
AKR1D1 rs75681380 7 137741527 0.28 All EPP MHT Use 0.36 1.43 0.92 1.29 4.35E-04 0.30 1.35 0.90 1.20 1.62E-02 0.33 1.39 0.99 1.30 1.73E-01
CYP11A1 rs9944175 15 74679948 0.13 All Breast Fed 0.31 1.37 0.85 1.17 7.69E-04 0.29 1.34 0.88 1.19 1.29E-02 0.27 1.32 0.73 0.99 2.09E-01
CYP11A1 rs9944175 15 74679948 0.13 All Endometriosis -0.50 0.61 1.09 0.69 7.86E-04 -0.87 0.42 1.12 0.47 4.13E-05 -0.37 0.69 0.96 0.79 1.78E-01
CYP1A1_2 rs183556665 15 74999266 0.11 All Endometriosis -0.60 0.55 1.02 0.58 7.98E-04 -0.72 0.49 1.04 0.51 2.75E-03 -0.88 0.41 1.01 0.47 1.10E-02
ESR1 rs1293950 6 151992921 0.26 All Breast Fed -0.24 0.79 1.22 0.96 3.38E-04 -0.14 0.87 1.13 0.98 9.48E-02 -0.35 0.70 1.47 1.04 1.63E-02
ESR1 rs12661437 6 152107936 0.20 All Endometriosis 0.53 1.71 0.92 1.59 1.47E-05 0.54 1.72 0.94 1.66 1.04E-03 0.45 1.58 0.91 1.43 3.91E-02
ESR1 rs3020327 6 152301645 0.11 All Parity -0.35 0.70 1.26 0.88 7.36E-04 -0.36 0.70 1.22 0.85 9.75E-03 -0.47 0.62 1.29 0.80 1.49E-02
FSHR rs7591064 2 49177601 0.18 All Estrogen Use -0.35 0.71 1.11 0.81 7.70E-04 -0.28 0.75 1.09 0.84 2.68E-02 -0.25 0.78 1.11 0.88 3.19E-01
IGF1R rs41497346 15 99485931 0.14 All EPP MHT Use -0.58 0.56 1.29 0.72 4.92E-06 -0.59 0.55 1.23 0.68 1.76E-04 -0.26 0.77 1.06 0.82 3.80E-01
IGFBP2_5 rs4674105 2 217499149 0.31 All OC Use 0.23 1.25 0.95 1.19 6.63E-04 0.22 1.25 0.96 1.22 8.68E-03 0.39 1.47 0.88 1.31 6.88E-03
IGHBP1_3 rs34416860 7 45910276 0.18 All Parity 0.30 1.35 0.81 1.09 1.40E-04 0.23 1.25 0.87 1.09 3.20E-02 0.37 1.44 0.80 1.13 1.51E-02
LHCGR rs4953625 2 48977778 0.30 All Estrogen Use 0.35 1.42 0.89 1.30 7.15E-04 0.33 1.39 0.87 1.25 9.95E-03 0.62 1.85 0.95 1.83 1.79E-02
PRLR rs10941235 5 35185580 0.29 All OC Use -0.18 0.84 1.05 0.87 6.69E-04 -0.12 0.89 1.01 0.90 8.80E-02 -0.12 0.89 1.00 0.89 2.95E-01
UGT1A134567910 rs17868323 2 234590970 0.42 All BMI -0.37 0.69 1.02 0.71 1.35E-04 -0.31 0.74 1.00 0.74 2.55E-02 -0.44 0.64 1.00 0.66 1.99E-02
AKR1C1_2_3 rs61856140 10 5111785 0.15 Endometrioid Estrogen Use -0.49 0.61 1.11 0.68 3.79E-04 -0.37 0.69 1.02 0.71 2.99E-02 -1.47 0.23 1.36 0.32 5.30E-05
AKR1C4 rs10795254 10 5236360 0.15 Endometrioid BMI -0.18 0.84 0.94 0.76 2.12E-01 0.00 1.00 0.93 0.90 9.91E-01 -1.16 0.31 1.01 0.31 8.45E-04
COMT rs740603 22 19945177 0.48 Endometrioid Breast Fed -0.03 0.97 1.04 1.01 6.63E-01 -0.15 0.86 1.12 0.96 4.66E-02 0.47 1.60 0.85 1.36 3.10E-04
CYP11B1_2 rs28526467 8 143996964 0.49 Endometrioid Endometriosis -0.22 0.80 1.01 0.83 1.47E-01 0.12 1.12 0.98 1.13 5.61E-01 -1.09 0.34 1.13 0.35 6.83E-05
CYP19A1 rs72729214 15 51643333 0.23 Endometrioid Estrogen Use 0.15 1.16 0.94 1.12 1.58E-01 -0.04 0.96 1.02 0.99 7.39E-01 0.80 2.23 0.82 1.90 9.80E-04
ESR2 rs17766755 14 64715773 0.34 Endometrioid OC Use -0.05 0.95 1.03 0.97 2.71E-01 0.02 1.02 1.02 1.04 7.43E-01 -0.38 0.68 1.10 0.75 4.79E-04
FSHR rs6708637 2 49241849 0.39 Endometrioid EPP MHT Use -0.17 0.85 1.08 0.92 5.07E-02 -0.08 0.92 1.11 1.04 4.30E-01 -0.66 0.52 1.18 0.61 8.64E-04
HSD17B2 rs2955162 16 82128777 0.26 Endometrioid Estrogen Use -0.23 0.80 0.98 0.80 2.50E-02 -0.11 0.90 0.94 0.85 3.87E-01 -1.12 0.32 1.09 0.34 3.44E-05
HSD17B3 rs6479221 9 99045539 0.17 Endometrioid Estrogen Use 0.07 1.08 1.08 1.17 5.65E-01 0.00 1.00 1.11 1.09 9.94E-01 1.28 3.61 0.87 2.86 5.57E-04
HSD17B4 rs11956614 5 118882502 0.17 Endometrioid EPP MHT Use -0.21 0.81 1.14 0.93 4.70E-02 -0.17 0.85 1.19 1.02 2.02E-01 -1.03 0.36 1.32 0.48 2.22E-04
IGF2R rs1867348 6 160456163 0.10 Endometrioid Endometriosis -0.22 0.81 0.97 0.72 2.07E-01 0.00 1.00 0.96 0.88 9.98E-01 -1.48 0.23 0.93 0.19 7.09E-04
INSR rs12463045 19 7295964 0.22 Endometrioid Tubal Ligation 0.25 1.28 0.94 1.21 3.67E-02 0.10 1.10 0.94 1.05 5.12E-01 1.14 3.14 0.80 2.51 6.08E-04
IRS2 rs12584564 13 110391742 0.42 Endometrioid BMI -0.15 0.86 1.06 0.90 1.42E-01 -0.19 0.83 1.06 0.84 1.99E-01 -0.80 0.45 1.10 0.47 3.14E-04
LHCGR rs12987764 2 48961338 0.21 Endometrioid Estrogen Use 0.30 1.35 0.90 1.22 7.25E-03 0.26 1.29 0.83 1.08 6.83E-02 0.97 2.63 0.91 2.43 1.10E-04
PRL rs72836169 6 22269312 0.11 Endometrioid OC Use -0.16 0.85 1.07 0.91 9.01E-02 -0.12 0.89 1.13 1.01 3.36E-01 -0.83 0.44 1.42 0.61 7.09E-05
PRLR rs13159459 5 35182738 0.11 Endometrioid Tubal Ligation -0.03 0.97 0.98 0.95 7.58E-01 0.06 1.07 0.94 1.02 6.36E-01 -1.35 0.26 0.98 0.25 3.93E-04
SHBG rs62453193 7 7538557 0.22 Endometrioid Parity 0.03 1.03 0.95 1.00 7.12E-01 -0.10 0.90 1.12 0.99 3.85E-01 0.61 1.85 0.61 1.16 5.19E-04
SRD5A1 rs8192125 5 6633447 0.22 Endometrioid Parity -0.08 0.93 1.11 1.04 3.30E-01 0.00 1.00 1.03 1.04 9.79E-01 -0.50 0.61 1.41 0.88 6.53E-04
UGT1A134567910 rs1587493 2 234689751 0.18 Endometrioid BMI -0.26 0.77 0.98 0.78 3.15E-02 -0.16 0.85 0.92 0.82 3.53E-01 -0.75 0.47 1.08 0.53 9.03E-04
UGT1A134567910 rs7581102 2 234694727 0.29 Endometrioid Estrogen Use 0.01 1.01 1.04 1.06 8.84E-01 -0.15 0.86 1.10 0.95 1.79E-01 0.80 2.22 0.90 1.85 2.04E-04
AKR1D1 rs6954846 7 137750696 0.22 High Grade Serous Breast Fed -0.20 0.82 1.18 0.98 1.10E-02 -0.34 0.71 1.25 0.90 6.51E-04 -0.19 0.83 1.38 1.14 3.10E-01
CYP11A1 rs9944175 15 74679948 0.13 High Grade Serous Endometriosis -0.50 0.61 1.09 0.69 7.86E-04 -0.87 0.42 1.12 0.47 4.13E-05 -0.37 0.69 0.96 0.79 1.78E-01
CYP1A1_2 rs2960192 15 75049943 0.39 High Grade Serous Endometriosis 0.21 1.24 0.97 1.23 2.45E-02 0.45 1.57 0.97 1.60 4.34E-04 -0.02 0.98 1.00 1.04 9.23E-01
ESR2 rs6573551 14 64738106 0.11 High Grade Serous Estrogen Use -0.43 0.65 1.05 0.66 3.63E-03 -0.73 0.48 1.20 0.56 1.03E-04 0.14 1.15 0.76 0.83 7.05E-01
HSD17B4 rs3797372 5 118870452 0.34 High Grade Serous OC Use 0.10 1.11 0.92 1.02 3.69E-02 0.22 1.24 0.85 1.07 9.23E-04 -0.02 0.98 0.96 0.94 8.48E-01
IGF1R rs12898261 15 99308666 0.32 High Grade Serous BMI -0.19 0.83 0.98 0.81 5.82E-02 -0.46 0.63 0.99 0.63 8.30E-04 0.10 1.11 0.88 1.02 6.12E-01
IGF1R rs28612945 15 99458902 0.18 High Grade Serous EPP MHT Use 0.43 1.54 0.85 1.34 1.04E-04 0.51 1.67 0.83 1.38 1.60E-04 0.20 1.22 0.97 1.27 4.36E-01
IGF1R rs7168671 15 99454962 0.18 High Grade Serous Estrogen Use 0.23 1.26 0.99 1.23 2.76E-02 0.44 1.55 0.95 1.46 5.55E-04 0.02 1.02 1.02 1.04 9.45E-01
INSR rs11880482 19 7131685 0.27 High Grade Serous BMI 0.26 1.29 0.95 1.20 1.68E-02 0.51 1.67 0.91 1.49 4.37E-04 0.20 1.22 1.02 1.23 3.54E-01
LHCGR rs36068361 2 48999621 0.16 High Grade Serous Breast Fed -0.25 0.78 1.25 0.98 8.58E-03 -0.45 0.64 1.44 0.93 2.70E-04 -0.15 0.86 1.18 1.03 4.74E-01
SRD5A1 rs274657 5 6680115 0.12 High Grade Serous Parity -0.22 0.80 1.18 0.96 2.92E-02 -0.44 0.64 1.39 0.91 8.40E-04 -0.03 0.97 0.96 0.97 8.79E-01
SULT1A1 rs11074905 16 28614472 0.44 High Grade Serous Endometriosis 0.20 1.22 0.99 1.21 1.46E-01 0.67 1.95 0.98 1.89 3.62E-04 -0.30 0.74 0.92 0.70 2.39E-01
UGT2B17 rs34664906 4 69433714 0.37 High Grade Serous OC Use -0.14 0.87 1.06 0.92 6.00E-02 -0.34 0.71 1.19 0.84 5.25E-04 0.22 1.25 0.83 1.04 1.84E-01
Supplementary Table 4. Candidate Gene GE Analyses top hits (p-value < 10
-3
)
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Gene SNP Chromosome Build 37 Position MAF Histology (Most Significant) Environment GEE Est (all) OR GEE (all) OR low bmi/no (all) OR low bmi/yes (all) OR high bmi/no (all) OR high bmi/yes (all) GEE LRT p-value (all) GEE Est (HGS) OR GEE (HGS) OR low bmi/no (HGS) OR low bmi/yes (HGS) OR high bmi/no (HGS) OR high bmi/yes (HGS) GEE LRT p-value (HGS) GEE Est (Endo) OR GEE (Endo) OR low bmi/no (Endo) OR low bmi/yes (Endo) OR high bmi/no (Endo) OR high bmi/yes (Endo) GEE LRT p-value (Endo)
AKR1D1 rs12671202 7 137822376 0.13 All Parity 1.32 3.73 1.24 1.00 0.55 1.58 3.25E-04 1.16 3.20 1.34 1.07 0.60 1.49 3.17E-02 1.65 5.21 1.53 0.96 0.67 1.49 8.79E-03
CYP11B1_2 rs6391 8 143956965 0.43 All Estrogen Use -2.55 0.08 1.09 0.95 0.92 0.03 2.72E-04 -2.46 0.09 1.11 0.88 0.82 0.00 1.36E-02 -1.83 0.16 1.11 1.46 0.46 0.00 1.54E-01
CYP11B1_2 rs80062072 8 143994398 0.32 All OC Use -1.17 0.31 1.14 1.08 2.01 0.57 6.28E-04 -1.07 0.34 1.14 1.11 1.53 0.54 2.59E-02 -0.46 0.63 1.33 0.93 1.97 0.81 5.08E-01
CYP11B1_2 rs11787475 8 143946223 0.14 All Parity 2.05 7.76 1.01 0.95 0.23 1.83 2.64E-04 2.00 7.38 1.21 1.01 0.23 1.50 1.83E-02 2.20 9.00 1.23 0.97 0.29 2.64 1.77E-02
ESR1 rs11155811 6 152077846 0.48 All EPP MHT Use -1.09 0.34 1.03 1.13 1.54 0.51 9.19E-04 -0.82 0.44 1.07 1.16 1.52 0.63 6.71E-02 -1.49 0.23 1.01 1.13 2.00 0.00 6.05E-02
FSHR rs1024776 2 49170035 0.21 All Parity 0.92 2.50 1.08 0.97 0.53 1.16 3.86E-04 0.89 2.44 1.00 0.94 0.57 1.00 2.78E-02 0.32 1.38 1.09 1.04 0.53 0.94 4.80E-01
HSD17B3 rs10125001 9 99023237 0.44 All Breast Fed -1.05 0.35 0.93 0.94 2.17 0.73 7.58E-04 -1.11 0.33 0.92 0.91 1.98 0.60 8.06E-03 -2.02 0.13 1.00 1.01 3.58 0.40 4.65E-03
HSD17B3 rs8190534 9 99018281 0.22 All Estrogen Use -2.50 0.08 1.09 1.09 0.93 0.05 5.78E-04 -4.42 0.01 1.09 1.06 0.87 0.00 3.00E-03 -0.84 0.43 1.03 1.20 1.00 0.10 4.76E-01
IGF1R rs1815007 15 99480263 0.39 All OC Use 0.68 1.98 1.08 0.94 0.81 1.32 6.14E-04 0.64 1.89 1.12 0.95 0.83 1.22 2.26E-02 0.57 1.77 1.13 0.89 1.03 1.79 1.43E-01
IGFBP2_5 rs869564 2 217500111 0.11 All Parity -2.34 0.10 0.90 1.04 5.78 0.52 1.43E-05 -2.56 0.08 0.78 1.08 7.49 0.69 1.12E-03 -1.22 0.30 0.97 1.12 1.99 1.02 1.98E-01
INSR rs7257990 19 7180910 0.12 All Endometriosis 2.29 9.85 1.06 1.19 0.70 15.31 6.68E-04 2.28 9.74 1.05 1.09 0.78 57.15 4.87E-03 2.68 14.63 1.20 1.50 0.58 8.00E+25 1.08E-02
IRS2 rs1755724 13 110417837 0.14 All Parity -1.63 0.20 0.66 1.07 2.45 0.73 3.92E-04 -1.75 0.17 0.66 0.98 4.22 0.70 1.08E-02 -1.50 0.22 0.61 1.20 1.30 0.72 7.38E-02
LHCGR rs12052559 2 48982174 0.18 All EPP MHT Use 1.53 4.62 0.98 1.07 0.70 6.34 8.96E-04 1.32 3.75 0.98 1.08 0.65 5.78 1.77E-02 1.76 5.78 0.95 1.13 0.62 6.55 6.18E-02
SST rs62277773 3 187372426 0.12 All EPP MHT Use 2.01 7.45 1.11 0.96 0.80 14.78 5.25E-04 2.13 8.43 1.13 0.82 1.45 28.29 2.40E-03 2.37 10.66 1.47 0.97 0.59 234.16 3.62E-02
UGT1A134567910 rs2011404 2 234627937 0.15 All Estrogen Use -1.98 0.14 0.97 1.28 1.10 0.09 1.81E-04 -2.65 0.07 0.90 1.12 1.02 0.00 3.01E-04 -0.45 0.64 1.16 1.36 0.54 2.17 6.60E-01
HSD17B2 rs3887358 16 82136566 0.12 Endometrioid Parity 0.37 1.44 1.06 1.01 0.95 1.04 3.11E-01 -0.02 0.98 0.89 1.07 0.70 0.95 9.67E-01 2.24 9.40 1.53 0.92 0.52 2.57 9.67E-04
INSR rs150197522 19 7249994 0.18 Endometrioid OC Use -1.26 0.28 0.84 1.12 1.49 0.65 1.52E-03 -1.14 0.32 0.83 1.18 1.25 0.77 4.44E-02 -3.81 0.02 1.03 1.17 1.60 0.06 1.81E-04
INSR rs8102954 19 7288771 0.37 Endometrioid Parity -0.31 0.73 1.10 1.05 1.19 0.84 3.24E-01 0.20 1.23 1.25 1.09 0.70 0.76 6.60E-01 -2.56 0.08 0.95 1.17 3.28 0.28 8.35E-06
IRS1 rs6725330 2 227666857 0.11 Endometrioid Parity -1.00 0.37 0.92 0.96 1.77 0.68 1.11E-02 -1.34 0.26 0.95 0.95 2.32 0.46 3.61E-02 -2.84 0.06 0.72 1.06 2.43 0.16 2.77E-04
IRS2 rs75453923 13 110418023 0.28 Endometrioid Parity -0.58 0.56 0.86 1.04 1.35 0.94 2.73E-02 -0.28 0.76 0.78 1.03 0.89 1.07 4.83E-01 -1.57 0.21 0.74 1.06 1.93 0.46 6.46E-04
PGR rs600677 11 100887598 0.30 Endometrioid Parity -0.47 0.63 0.96 1.00 1.47 0.93 4.15E-02 -0.20 0.82 1.03 0.95 1.40 0.96 5.55E-01 -1.47 0.23 1.02 1.15 3.44 0.63 3.41E-04
AKR1C1_2_3 rs4881390 10 5108821 0.30 High Grade Serous Breast Fed 0.45 1.57 0.97 1.03 0.70 1.26 9.16E-02 1.25 3.48 1.06 1.10 0.54 1.93 4.71E-04 -0.61 0.54 0.71 0.97 0.87 0.69 2.94E-01
COMT rs72195121 22 20017857 0.50 High Grade Serous Endometriosis -1.01 0.36 0.98 1.10 1.09 0.37 1.32E-02 -2.29 0.10 1.01 1.21 1.13 0.06 2.31E-04 -0.46 0.63 1.06 0.95 1.21 9.97E+13 5.38E-01
CYP11B1_2 rs113759408 8 143958342 0.22 High Grade Serous OC Use 1.02 2.77 0.99 1.03 0.51 1.73 1.25E-03 1.79 5.97 1.03 0.96 0.46 3.24 4.68E-05 0.74 2.11 0.98 1.05 0.45 1.10 2.43E-01
GNRHR rs148964181 4 68607384 0.12 High Grade Serous OC Use 0.52 1.68 1.08 1.00 0.81 1.33 1.67E-01 1.81 6.10 0.98 0.92 0.40 2.33 7.86E-04 -1.12 0.33 1.03 1.08 1.70 0.89 1.45E-01
IGF1R rs8034564 15 99190601 0.43 High Grade Serous EPP MHT Use 1.48 4.38 0.93 1.06 0.58 3.94 3.47E-04 2.16 8.63 0.93 1.08 0.50 7.86 2.35E-04 0.47 1.59 0.92 1.03 0.66 1.01 5.91E-01
IGF1R rs12591120 15 99236869 0.25 High Grade Serous Tubal Ligation -0.46 0.63 1.00 1.02 1.10 0.79 8.03E-02 -1.20 0.30 1.04 1.00 1.48 0.47 9.65E-04 -0.36 0.70 1.11 1.22 0.75 0.61 6.63E-01
IGFBP2_5 rs56024880 2 217495408 0.30 High Grade Serous EPP MHT Use 1.73 5.64 1.08 1.02 0.73 4.70 1.16E-03 1.77 5.84 1.06 1.20 0.74 7.44 9.55E-04 2.91 18.39 1.00 0.93 0.23 4.54 1.39E-02
INHBB rs11902591 2 121106003 0.11 High Grade Serous Tubal Ligation 1.37 3.95 0.94 1.07 0.86 4.47 9.77E-03 2.63 13.87 0.98 0.73 0.44 6.42 1.78E-04 1.04 2.82 0.85 2.38 0.98 451.13 4.59E-01
IRS2 rs12586052 13 110391499 0.43 High Grade Serous Parity -0.35 0.71 1.08 1.06 1.25 0.86 1.73E-01 -1.53 0.22 1.04 1.05 4.30 0.75 1.28E-04 0.28 1.32 1.47 1.14 0.78 0.63 5.44E-01
UGT1A134567910 rs2011404 2 234627937 0.15 High Grade Serous Estrogen Use -1.98 0.14 0.97 1.28 1.10 0.09 1.81E-04 -2.65 0.07 0.90 1.12 1.02 0.00 3.01E-04 -0.45 0.64 1.16 1.36 0.54 2.17 6.60E-01
UGT2B17 rs59678213 4 69434357 0.44 High Grade Serous Parity 0.40 1.49 1.12 0.98 0.72 0.83 2.55E-01 1.81 6.09 1.14 0.95 0.22 1.04 7.61E-04 -0.83 0.44 1.27 0.96 1.29 0.44 1.79E-01
Supplementary Table 5. Candidate Gene BMI-GE Analyses top hits (p-value < 10 -3)
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Low or Normal (< 25) High or Obese (>25) Totals
Controls 7607 679 8286
All Invasive Cases 4427 508 4935
High Grade Serous 2103 193 2296
Endometrioid 680 98 778
Totals 12034 1187 13221
1 or less childbirth
More than 1 child 
birth
Totals
Controls 2837 6812 9649
All Invasive Cases 2352 3429 5781
High Grade Serous 940 1764 2704
Endometrioid 446 441 887
Totals 5189 10241 15430
Less than 2 years More than 2 years Totals
Controls 4895 5428 10323
All Invasive Cases 3487 2616 6103
High Grade Serous 1716 1237 2953
Endometrioid 538 407 945
Totals 8382 8044 16426
Never Ever Totals
Controls 2312 5320 7632
All Invasive Cases 1641 2467 4108
High Grade Serous 834 1227 2061
Endometrioid 235 336 571
Totals 3953 7787 11740
Never Ever Totals
Controls 8738 568 9306
All Invasive Cases 4802 533 5335
High Grade Serous 2366 212 2578
Endometrioid 701 114 815
Totals 13540 1101 14641
Never Ever Totals
Controls 3420 1631 5051
All Invasive Cases 2105 765 2870
High Grade Serous 1024 452 1476
Endometrioid 301 104 405
Totals 5525 2396 7921
Never Ever Totals
Controls 3986 1068 5054
All Invasive Cases 2250 631 2881
High Grade Serous 1124 356 1480
Endometrioid 328 77 405
Totals 6236 1699 7935
Endometrioisis
MHT Combination Use
HRT Estrogen Use
Supplementary Table 6: Sample Sizes by Low/High status across 
environmental factors.
Young Adult BMI
Parity
Oral Contraceptive Use
Breast Fed
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Supplementary Table 7: Sample Sizes by young adult BMI (Low/High) and Environmental (Low/High) status across 7 environmental factors.
1 or less childbirth More than 1 child birth 1 or less childbirth More than 1 child birth Totals
Controls 2090 5516 231 447 8284
All Cases 1643 2783 232 276 4934
High-Grade Serous 659 1444 69 124 2296
Endometrioid 307 373 58 40 778
Totals 3733 8299 463 723 13218
Less than 2 years More than 2 years Less than 2 years More than 2 years Totals
Controls 3716 3858 327 349 8250
All Cases 2493 1898 312 195 4898
High-Grade Serous 1208 872 120 72 2272
Endometrioid 388 288 52 46 774
Totals 6209 5756 639 544 13148
Never Ever Never Ever Totals
Controls 1960 4467 191 354 6972
All Cases 1395 2091 145 200 3831
High-Grade Serous 711 1048 62 89 1910
Endometrioid 202 291 25 29 547
Totals 3355 6558 336 554 10803
Never Ever Never Ever Totals
Controls 6610 434 598 34 7676
All Cases 3682 416 433 39 4570
High-Grade Serous 1806 161 168 15 2150
Endometrioid 531 88 79 9 707
Totals 10292 850 1031 73 12246
No Yes No Yes Totals
Controls 5419 1604 479 170 7672
All Cases 3599 697 408 75 4779
High-Grade Serous 1656 395 146 42 2239
Endometrioid 578 80 86 5 749
Totals 9018 2301 887 245 12451
Never Ever Never Ever Totals
Controls 2404 1215 215 78 3912
All Cases 1542 567 157 33 2299
High-Grade Serous 741 319 61 20 1141
Endometrioid 214 76 28 6 324
Totals 3946 1782 372 111 6211
Never Ever Never Ever Totals
Controls 2793 828 228 65 3914
All Cases 1593 525 166 26 2310
High-Grade Serous 771 292 73 9 1145
Endometrioid 225 65 28 6 324
Totals 4386 1353 394 91 6224
Low BMI High BMI
Estrogen Plus Progesterone MHT
Low BMI
Low BMI High BMI
Estrogen only MHT
High BMI
Low BMI High BMI
Parity 
Oral Contraceptive Use
Breast Feeding
Endometriosis
Tubal Ligation
Low BMI High BMI
Low BMI High BMI
Low BMI High BMI
